Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immune Response and Risk of Decompensation following SARS-CoV-2 Infection in Outpatients with Advanced Chronic Liver Disease

  • Brujats Rubirola, Anna|||0000-0003-3317-0295
  • Huerta, Anna|||0000-0002-2524-770X
  • Osuna Gómez, Rubén|||0000-0003-2875-4405
  • Guinart Cuadra, Albert|||0000-0003-0233-5595
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Pujol Camps, Clàudia|||0000-0002-3238-2547
  • Soriano, German|||0000-0002-9267-6811
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Fajardo Ordoñez, Javier|||0009-0001-7716-1908
  • Escorsell, Àngels|||0000-0001-5083-8467
  • Gallego Moya, Adolfo|||0000-0002-8423-6787
  • Vidal, Silvia|||0000-0002-3909-6682
  • Villanueva, Càndid|||0000-0002-3674-914X
  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
Advanced chronic liver disease (ACLD) is associated with a wide spectrum of immune dysfunction. The clinical impact of SARS-CoV-2 on the development of decompensation and immune response in unvaccinated outpatients has not as yet been clearly defined. This study aimed to evaluate the clinical and immunological impact of SARS-CoV-2 on outpatients with ACLD. This is an observational case-control study, in which ACLD outpatients were included prospectively and consecutively and classified into two groups: SARS-CoV-2 infected and non-infected. Patients' baseline characteristics and infection data were collected and analyzed. Immunoglobulin G (IgG) levels against Spike 1 were evaluated. The primary endpoint was risk of liver decompensation during follow-up, assessed after propensity score matching and adjusted by Cox regression. Between October 2020 and July 2021, ACLD outpatients (n = 580) were identified, and 174 patients with clinical follow-up were included. SARS-CoV-2 infection incidence was 7.6% (n = 44). Risk of liver decompensation was significantly higher after infection (HR = 2.43 [1.01-5.86], p = 0.048) vs. non-infection. The time of IgG evaluation was similar in all patients (n = 74); IgG concentrations were significantly higher in compensated vs. decompensated patients (1.02 ± 0.35 pg/mL vs. 0.34 ± 0.16 pg/mL, p < 0.0001) and correlated with hemoglobin levels. The dysregulation of the innate immune response in patients with decompensated liver disease increased the risk of further decompensation following SARS-CoV-2, mainly due to a worsening of ascites.